MONTREAL, CANADA--(Marketwire - May 14, 2008) - Theratechnologies (TSX: TH) advises of an upcoming conference call and webcast to discuss the signing of a strategic agreement to explore the use of tesamorelin in an additional indication. The call will be moderated by Dr. Andrea Gilpin, Executive Director, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating.
